Combined-modality radioimmunotherapy: Synergistic effect of paclitaxel and additive effect of bevacizumab

Nuclear Medicine and Biology

Volumn 39, Issue 4, 2012, Pages 472-483

  Jang, Beom Su ^a,d,e   Lee, Sang Myung ^a,d,e   Kim, Hyung Sub ^a   Shin, In Soo ^a   Razjouyan, Faezeh ^b   Wang, Shutao ^b   Yao, Zhengsheng ^a   Pastan, Ira ^c   Dreher, Matthew R ^b   Paik, Chang H ^a  

^a Radiopharmaceutical Laboratory   (United States)

^b CLINICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Korea Atomic Energy Research Institute   (South Korea)

^e Kangwon National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY Y 90; PACLITAXEL; UNCLASSIFIED DRUG; YTTRIUM MONOCLONAL ANTIBODY B3 Y 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; MICE; MICROSCOPY, FLUORESCENCE; MICROVESSELS; PACLITAXEL; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 84860325377     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.10.020     Document Type: Article

References (66)

1. Macklis R.M., Beresford B.A., Palayoor S., Sweeney S., Humm J.L. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys 1993, 27:643-650.
2. Kroger L.A., DeNardo G.L., Gumerlock P.H., Xiong C.Y., Winthrop M.D., Shi X.B., et al. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm 2001, 16:213-225.
3. Kaminski M.S., Zelenetz A.D., Press O.W., Saleh M., Leonard J., Fehrenbacher L., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
4. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-2463.
5. Weigert O., Illidge T., Hiddemann W., Dreyling M. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006, 107:686-695.
6. Waldmann T.A., White J.D., Carrasquillo J.A., Reynolds J.C., Paik C.H., Gansow O.A., et al. Radioimmunotherapy of interleukin-2r-alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 1995, 86:4063-4075.
7. DeNardo G.L., Sysko V.V., DeNardo S.J. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys 2006, 66:S46-S56.
8. Mulligan T., Carrasquillo J.A., Chung Y., Milenic D.E., Schlom J., Feuerstein I., et al. Phase I study of intravenous Lu-177-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995, 1:1447-1454.
9. Yu B., Carrasquillo J., Milenic D., Chung Y., Perentesis P., Feuerestein I., et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996, 14:1798-1809.
10. Pai-Scherf L.H., Carrasquillo J.A., Paik C., Gansow O., Whatley M., Pearson D., et al. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3. Clin Cancer Res 2000, 6:1720-1730.
11. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure-gradients in tissue-isolated and subcutaneous tumors - implications for therapy. Cancer Res 1990, 50:4478-4484.
12. Fujimori K., Covell D.G., Fletcher J.E., Weinstein J.N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990, 31:1191-1198.
13. Saga T., Neumann R.D., Heya T., Sato J., Kinuya S., Le N., et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A 1995, 92:8999-9003.
14. Christiansen J., Rajasekaran A.K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 2004, 3:1493-1501.
15. Jain M., Venkatraman G., Batra S.K. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res 2007, 13:1374-1382.
16. Zhang Y., Xiang L., Hassan R., Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 2007, 104:17099-17104.
17. Hauck M.L., Zalutsky M.R. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: application of the thermal equivalency equation. Int J Hyperthermia 2005, 21:13-27.
18. Khaibullina A., Jang B.S., Sun H., Le N., Yu S., Frenkel V., et al. Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J Nucl Med 2008, 49:295-302.
19. De Brabander M., Geuens G., Nuydens R., Willebrords R., De Mey J. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci U S A 1981, 78:5608-5612.
20. Manfredi J.J., Horwitz S.B. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984, 25:83-125.
21. Moos P.J., Fitzpatrick F.A. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ 1998, 9:687-697.
22. Blagosklonny M.V., Schulte T., Nguyen P., Trepel J., Neckers L.M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996, 56:1851-1854.
23. Oyaizu H., Adachi Y., Taketani S., Tokunaga R., Fukuhara S., Ikehara S. A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis. Mol Cell Biol Res Commun 1999, 2:36-41.
24. Kataja V., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl 2):ii11-ii13.
25. Beslija S., Bonneterre J., Burstein H.J., Cocquyt V., Gnant M., Heinemann V., et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009, 20:1771-1785.
26. National Comprehensive Cancer Network NCCN guidelines 2009 [9 July 2009, date last accessed]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
27. DeNardo S.J., Kukis D.L., Kroger L.A., O'Donnell R.T., Lamborn K.R., Miers L.A., et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 1997, 94:4000-4004.
28. O'Donnell R.T., DeNardo S.J., Miers L.A., Lamborn K.R., Kukis D.L., DeNardo G.L., et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 2002, 50:27-37.
29. Blumenthal R.D., Leone E., Goldenberg D.M. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res 2003, 23:4613-4619.
30. Masters G.R., Berger M.A., Albone E.F. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts. Gynecol Oncol 2006, 102:462-467.
31. Kelly M.P., Lee F.T., Smyth F.E., Brechbiel M.W., Scott A.M. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med 2006, 47:716-725.
32. Miers L., Lamborn K., Yuan A., Richman C., Natarajan A., Denardo S., et al. Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers. Clin Cancer Res 2005, 11:7158s-7163s.
33. Taghian A.G., Abi-Raad R., Assaad S.I., Casty A., Ancukiewicz M., Yeh E., et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005, 23:1951-1961.
34. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
35. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
36. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
37. Kaku T., Kamura T., Kinukawa N., Kobayashi H., Sakai K., Tsuruchi N., et al. Angiogenesis in endometrial carcinoma. Cancer 1997, 80:741-747.
38. Kirschner C.V., Alanis-Amezcua J.M., Martin V.G., Luna N., Morgan E., Yang J.J., et al. Angiogenesis factor in endometrial carcinoma: a new prognostic indicator?. Am J Obstet Gynecol 1996, 174:1879-1882. [discussion 82-4].
39. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
40. Marty M., Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 2008, 44:912-920.
41. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
42. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
43. Genentech, Inc US prescribing information for Avastin. 2009 [11 March 2010, date last accessed]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf.
44. F.Hoffmann-La Roche Ltd Avastin summary of product characteristics. 2009 [11 March 2010, date last accessed]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/emea-combinedh582en.pdf.
45. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
46. Ma J., Waxman D.J. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008, 7:3670-3684.
47. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De Wever J., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005, 11:743-750.
48. Dings R.P., Loren M., Heun H., McNiel E., Griffioen A.W., Mayo K.H., et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007, 13:3395-3402.
49. Salaun P.Y., Bodet-Milin C., Frampas E., Oudoux A., Sai-Maurel C., Faivre-Chauvet A., et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer 2010, 116:1053-1058.
50. Chan A., Miles D.W., Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010, 21:2305-2315.
51. Pastan I., Lovelace E.T., Gallo M.G., Rutherford A.V., Magnani J.L., Willingham M.C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 1991, 51:3781-3787.
52. Camera L., Kinuya S., Garmestani K., Brechbiel M.W., Wu C., Pai L.H., et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med 1994, 21:640-646.
53. Camera L., Kinuya S., Garmestani K., Pai L.H., Brechbiel M.W., Gansow O.A., et al. Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts. Nucl Med Biol 1993, 20:955-962.
54. Yao Z., Zhang M., Axworthy D.B., Wong K.J., Garmestani K., Park L., et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N' ,N' '-tetraacetic acid (DOTA)-biotin. Cancer Res 2002, 62:5755-5760.
55. Dreher M.R., Liu W.G., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer I 2006, 98:335-344.
56. Bozec A., Sudaka A., Fischel J.L., Brunstein M.C., Etienne-Grimaldi M.C., Milano G. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008, 99:93-99.
57. Zhang Y., Xiang L., Hassan R., Paik C.H., Carrasquillo J.A., Jang B.S., et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006, 12:4695-4701.
58. Holden S.A., Lan Y., Pardo A.M., Wesolowski J.S., Gillies S.D. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001, 7:2862-2869.
59. Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
60. Varallyay C.G., Muldoon L.L., Gahramanov S., Wu Y.J., Goodman J.A., Li X., et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cerebr Blood F Met 2009, 29:853-860.
61. Griffon-Etienne G., Boucher Y., Brekken C., Suit H.D., Jain R.K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999, 59:3776-3782.
62. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
63. Wachsberger P., Burd R., Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003, 9:1957-1971.
64. Kim Y.C., Kim Y.H., Uhm S.H., Seo Y.S., Park E.K., Oh S.Y., et al. Radiation safety issues in Y-90 microsphere selective hepatic radioembolization therapy: possible radiation exposure from the patients. Nucl Med Mol Imaging 2010, 44:252-260.
65. Koppe M.J., Bleichrodt R.P., Soede A.C., Verhofstad A.A., Goldenberg D.M., Oyen W.J., et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004, 45:1224-1232.
66. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.